Trends in utilization and clinical outcomes with and without the use of distal filter wire embolic protection devices.

IF 1.6 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Cardiovascular Revascularization Medicine Pub Date : 2024-10-28 DOI:10.1016/j.carrev.2024.10.008

Timothy G Scully, Louise Roberts, Diem Dinh, Angela Brennan, David Clark, Andrew Ajani, Christopher M Reid, Ernesto Oqueli, Chin Hiew, Dion Stub, Jaya Chandrasekhar, Melanie Freeman

{"title":"Trends in utilization and clinical outcomes with and without the use of distal filter wire embolic protection devices.","authors":"Timothy G Scully, Louise Roberts, Diem Dinh, Angela Brennan, David Clark, Andrew Ajani, Christopher M Reid, Ernesto Oqueli, Chin Hiew, Dion Stub, Jaya Chandrasekhar, Melanie Freeman","doi":"10.1016/j.carrev.2024.10.008","DOIUrl":null,"url":null,"abstract":"Background: Embolic protection devices were developed to reduce the risk of common complications encountered during percutaneous coronary intervention (PCI) of saphenous vein grafts, however, in the setting of contemporary multi-modality medical management, their overall efficacy has been called into question. This study aimed to assess the evolving utilization and clinical outcomes associated with distal filter wire embolic protection devices in saphenous vein PCI.Methods: Consecutive patients undergoing PCI to a saphenous vein graft in a registry were included. Peri-procedural and long-term outcomes including 12-month mortality and 30-day MACCE rates were compared between PCI using a distal filter wire embolic protection device and unprotected PCI.Results: From 2005 to 2020, a total of 753 patients underwent PCI to a saphenous vein graft with 256 using a distal filter wire embolic protection device. At one year, the use of a distal filter wire embolic protection devices was not associated with a decrease in mortality (4.7 % vs 5.4 %, p = 0.19) and there was no difference in 30-day MACCE rates between protected and unprotected saphenous vein PCI (3.1 % vs 5.8 %, p = 0.10).Conclusion: In this 12-month analysis of saphenous vein graft PCI, there was no evidence that distal filter wire embolic protection devices improved short term post procedural or long-term mortality outcomes.","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":null,"pages":null},"PeriodicalIF":1.6000,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiovascular Revascularization Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.carrev.2024.10.008","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Embolic protection devices were developed to reduce the risk of common complications encountered during percutaneous coronary intervention (PCI) of saphenous vein grafts, however, in the setting of contemporary multi-modality medical management, their overall efficacy has been called into question. This study aimed to assess the evolving utilization and clinical outcomes associated with distal filter wire embolic protection devices in saphenous vein PCI.

Methods: Consecutive patients undergoing PCI to a saphenous vein graft in a registry were included. Peri-procedural and long-term outcomes including 12-month mortality and 30-day MACCE rates were compared between PCI using a distal filter wire embolic protection device and unprotected PCI.

Results: From 2005 to 2020, a total of 753 patients underwent PCI to a saphenous vein graft with 256 using a distal filter wire embolic protection device. At one year, the use of a distal filter wire embolic protection devices was not associated with a decrease in mortality (4.7 % vs 5.4 %, p = 0.19) and there was no difference in 30-day MACCE rates between protected and unprotected saphenous vein PCI (3.1 % vs 5.8 %, p = 0.10).

Conclusion: In this 12-month analysis of saphenous vein graft PCI, there was no evidence that distal filter wire embolic protection devices improved short term post procedural or long-term mortality outcomes.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

使用和未使用远端滤线栓塞保护装置的使用趋势和临床结果。

背景：栓塞保护装置的开发是为了降低大隐静脉移植物经皮冠状动脉介入治疗（PCI）过程中常见并发症的风险，然而，在现代多模式医疗管理的背景下，其整体疗效受到了质疑。本研究旨在评估远端滤线栓塞保护装置在大隐静脉PCI中的使用情况和临床效果：方法：纳入在登记处接受大隐静脉移植 PCI 的连续患者。比较了使用远端滤线栓塞保护装置和未使用保护装置的PCI的围手术期和长期结果，包括12个月死亡率和30天MACCE率：2005年至2020年，共有753名患者接受了大隐静脉移植PCI，其中256人使用了远端滤线栓塞保护装置。一年后，使用远端滤线栓塞保护装置与死亡率下降无关（4.7% vs 5.4%，P = 0.19），受保护和未受保护的隐静脉PCI的30天MACCE率也没有差异（3.1% vs 5.8%，P = 0.10）：在这项为期12个月的隐静脉移植PCI分析中，没有证据表明远端滤线栓塞保护装置能改善术后短期或长期死亡率。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Cardiovascular Revascularization Medicine CARDIAC & CARDIOVASCULAR SYSTEMS-

CiteScore

3.30

自引率

5.90%

发文量

687

审稿时长

36 days

期刊介绍： Cardiovascular Revascularization Medicine (CRM) is an international and multidisciplinary journal that publishes original laboratory and clinical investigations related to revascularization therapies in cardiovascular medicine. Cardiovascular Revascularization Medicine publishes articles related to preclinical work and molecular interventions, including angiogenesis, cell therapy, pharmacological interventions, restenosis management, and prevention, including experiments conducted in human subjects, in laboratory animals, and in vitro. Specific areas of interest include percutaneous angioplasty in coronary and peripheral arteries, intervention in structural heart disease, cardiovascular surgery, etc.